PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Junya OHMORI	03/18/2010
Makoto KASAI	03/23/2010
Takenori KIMURA	03/18/2010
Noritaka HAMADA	03/24/2010
Ryo MIZOGUCHI	03/24/2010
Satoshi MIYAMOTO	03/24/2010
Noriyuki KAWANO	03/24/2010

RECEIVING PARTY DATA

Name:	ASTELLAS PHARMA INC.
Street Address:	3-11, Nihonbashi-Honcho 2-chome, Chuo-ku
City:	Tokyo
State/Country:	JAPAN
Postal Code:	103-8411

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	12753415

CORRESPONDENCE DATA

(202)293-7860 Fax Number:

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 2022937060

Email: CGREEN@SUGHRUE.COM SUGHRUE MION PLLC Correspondent Name:

2100 PENNSYLVANIA AVE NW Address Line 1:

Address Line 4: WASHINGTON, DISTRICT OF COLUMBIA 20037-3213

ATTORNEY DOCKET NUMBER: Q118352

REEL: 024180 FRAME: 0527

PATENT

NAME OF SUBMITTER:	Mark Boland
Total Attachments: 1 source=Assignment#page1.tif	

PATENT REEL: 024180 FRAME: 0528

ASSIGNMENT

Whereas, I/we Junya OHMORI, Makoto KASAI, Takenori KIMURA, Noritaka HAMADA, Ryo MIZOGUCHI, Satoshi MIYAMOTO and Noriyuki KAWANO, all of Tokyo, Japan

hereinafter called assignor(s), have invented certain improvements in NOVEL SALT OF 1,3,5-TRIAZINE-2,4,6-TRIAMINE DERIVATIVE and executed an application for Letters Patent of the United States of America therefor on

March 18, 23 and 24, 201

2010; and

Whereas.

RECORDED: 04/02/2010

ASTELLAS PHARMA INC.

3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8411 Japan

(assignee), desires to acquire the entire right, title and interest in the application and invention, and to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named assignee, its successors and assigns, the entire right, title and interest in the application and the invention disclosed therein for the United States of America, including the right to claim priority under 35 U.S.C. § 119, and I/we request the Director – U.S. Patent and Trademark Office to issue any Letters Patent granted upon the invention set forth in the application to the assignee, its successors and assigns; and I/we will execute without further consideration all papers deemed necessary by the assignee in connection with the United States application when called upon to do so by the assignee.

I/We hereby authorize and request my/our attorneys SUGHRUE MION, PLLC of 2100

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. §261)

PATENT REEL: 024180 FRAME: 0529